Animalcare Group (ANCR) investor relations material

Strategic transformation and growth trajectory

• Transitioned from a fragmented, highly leveraged business to a focused, growth-oriented platform with reduced debt and a streamlined portfolio by end of 2025.

• Top 10 products now drive organic growth, with gross margin rising from 56% to 65% and owned/licensed products comprising 95% of revenue.

• Randlab acquisition in 2025 validated the M&A strategy, maintaining brand momentum and exceeding projections.

• Double-digit revenue growth targeted by 2030, aiming for ~£150m, with significant upside from new product development and acquisitions.

• Strategic investments in sales force, commercial excellence, and dental channel expansion underpin near-term growth.

Commercial excellence and operational efficiency

• Enhanced commercial capabilities deliver revenue growth 2% higher and earnings growth 5% higher than peers.

• Systemic commercial excellence in Germany led to 35% sales growth for Daxocox and 21% for Plaqtiv+ in 2025.

• Accelerated initiatives include expanding sales capacity, capability building, and onboarding to drive incremental EBITDA from 2027.

• Manufacturing network optimization underway, targeting full completion by 2029 to improve supply performance and capacity.

Multi-channel and innovation-driven expansion

• Dental franchise expansion into retail and online channels targets a 20% CAGR, leveraging digital marketing and retail partnerships.

• Rights to all channels in Europe for Plaqtiv+ and global rights for Orozyme position the business for significant dental revenue growth by 2030.

• R&D investment focused on cross-species drug discovery, with a lean, flexible operational model and robust risk management.

• Pipeline includes proprietary pharmaceuticals and biologics, with NPD contributing from 2029 and transformational growth expected post-2030.

• VHH antibody technology acquisition provides entry into a projected $2–3bn companion animal pain market by 2033.